Section Editor: Gerald L. Andriole, Jr., MD

Cancer diagnosis and therapy is becoming more focused toward a patient-specific approach to therapy, particularly prostate cancer. The role of imaging is paramount in this evolution by providing physicians with accurate information on both the presence and extent of prostate cancers. Developments in molecular imaging are paving the way for more physicians to diagnose cancer and apply relevant therapy. Various imaging modalities and methods may be best suited for different phases of the disease. Our associated physicians discuss the importance of imaging in more detail below.


Incorporating New PET Imaging and Theranostic Approaches into Prostate Cancer Practice

Phillip J. Koo, MD, chair of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), discusses advances in nuclear medicine and imaging, basic concepts of the theranostic approach, and controversies in this field. Following Dr. Koo’s discussion of the current state of nuclear medicine, Susan F. Slovin, MD, PhD, discusses the three iterations of the Radiographic Assessments for Detection of Advanced Recurrence (RADAR).





Dr. Calais - PSMA

Current Status of PSMA Diagnostics

Jeremie Calais, MD, MSc, discusses PSMA diagnostics and compares imaging modalities to establish which modality is ideal for prostate cancer staging.
Dr. Koo - NGI

Next Generation Imaging for Prostate Cancer

Phillip J. Koo, MD, gives an overview of the current state of next generation imaging for prostate cancer and how it compares to conventional imaging.
Dr. Tempany - Risk Assessment Biopsy

Current and Emerging Imaging Tools for Improving Risk Assessment and Selection of Patients for Biopsy

Clare Tempany, MD, summarizes evidence for mpMRI’s use in PCa diagnosis, and goes over recent developments in risk assessment & biopsy.
Dr. Iagaru - Molecular Imaging Prostate Cancer

Non-Invasive Molecular Imaging and its Impact on Management of the Localized Disease and Suspected Recurrence

Andrei H. Iagaru, MD, FACNM, enumerates applications of dual radiopharmaceutical-targeted imaging with PSMA & GRPR in prostate cancer care.
Dr. George - TheraP Lu-PSMA-617

TheraP Trial and Effectiveness of Lu-PSMA-617

Daniel J. George, MD, comments on the TheraP trial that compared Lu-PSMA-617 against cabazitaxel in mCRPC patients.
Dr. Punnen - Multimodal Imaging

Integrated Multi-Modality Diagnostic Evaluation of Prostate Cancer

Sanoj Punnen, MD, MAS, specifies how multimodal detection options for prostate cancer could improve and personalize diagnosis.
Dr. Weber - Imaging and Theranostics

Current State-of-the-Art Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer

Wolfgang Weber, MD, reviews a half-decade of progress in the field of prostate cancer imaging and theranostics.
Dr. Raman - Whole Gland Treatment

Image-Guided Minimally-Invasive Whole Gland Treatment

Steven S. Raman, MD, explains how MRI aids in prostate cancer staging, diagnosis, follow-up, treatment planning, and image-guided treatment.
Dr. Koo - Nuclear Medicine

Future Directions in Molecular and Multi-Modality Imaging and Theranostics of Prostate Cancer

Phillip J. Koo, MD, discusses clinical, research, and educational targets advancing nuclear medicine’s role in prostate cancer treatment.
Dr. Klotz - miR Scientific

The miR Scientific Sentinel Assay

Laurence Klotz, MD, Professor of Surgery at the University of Toronto, discusses the miR Scientific Sentinel Assay.
Dr. Polascik - Focal therapy prostate cancer

Updates in Focal Therapy of Prostate Cancer

Thomas J. Polascik, MD, FACS, Professor of Urology at Duke University Medical Center, discusses the effectiveness of focal therapy for prostate cancer as an alternative to radical therapy.

Molecular Imaging of Prostate Cancer

Wolfgang Weber, MD, Professor and Chair of the Department of Nuclear Medicine at the Technical University of Munich in Germany, discusses the changes in molecular imaging over the last 7 years and their impact on staging and re-staging of prostate cancer. Dr. Weber discusses how PSMA PET imaging works by binding with the ligands of antigens present in cells affected by prostate cancer.


Gerald L. Andriole, Jr., MD
Barnes-Jewish Hospital and Washington University School of Medicine
St. Louis, Missouri

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 35 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 400 peer-reviewed publications and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and PI of the NIDDK Multidisciplinary Approach to Urologic Pelvic Pain (MAPP) and Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN). He was Chairman of the Steering Committee of the REDUCE Prostate Cancer Prevention Trial as well as PI of the NIDDK Medical Therapy of Prostatic Symptoms (MTOPS) BPH trial, and of the NIDDK Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) study. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association, the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons, among other societies.

Supported in part by Blue Earth Diagnostics, Inc.